Moderna, Inc.

MRNAintermediary

Moderna pioneered commercial mRNA technology with its COVID-19 vaccine and is now building a multi-product mRNA platform spanning infectious disease, oncology, and rare genetic disorders. Its RSV vaccine approval and cancer-vaccine pipeline represent the next phase of mRNA's therapeutic potential.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($8.8B)

Data statis (memuat keuangan langsung…)

COVID-19 Vaccines (62%)

RSV Vaccine (20%)

Grants & Collaborations (10%)

Other Pipeline Products (8%)

Komposisi segmen dan pelanggan utama

Detail produk

Spikevax (COVID-19 Vaccine)50%

mRNA-based COVID-19 vaccine and updated boosters

mRNA-1345 (RSV Vaccine)18%

mRNA respiratory syncytial virus vaccine

Flu/COVID Combo Vaccine5%

Combined influenza and COVID mRNA vaccine in late-stage trials

Oncology mRNA (INT-0167)3%

Individualized neoantigen mRNA cancer vaccines

Rare Disease Pipeline4%

mRNA therapeutics for genetic disorders (PA, MMA)

Hubungan Rantai Pasok

Pesaing

Pfizer Inc.

mRNA vaccines

Dampak: Primary vaccine competitor

Regeneron Pharmaceuticals

Oncology immunotherapy

Dampak: Competing in cancer vaccines

Mitra

Eli Lilly and Company

Potential mRNA oncology collaboration

Dampak: Exploratory

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Masalah rantai pasokan

★ 기회mRNA-4157 암백신 FDA 우선심사 신청

2026-04

Merck와 공동 개발 mRNA-4157/V940 흑색종 보조요법 BLA 제출 예정. 우선심사 적용 시 2026H2 승인 가능.

⚡ 리스크RSV 백신 경쟁 심화 — 매출 전망 하향

2026-03

Pfizer·GSK RSV 백신 시장 공유로 MRNA RSV 점유율 17%에 그침. 2026 RSV 매출 가이던스 하향 조정.

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Moderna, Inc..

Info Perusahaan

Kantor Pusat

Cambridge, Massachusetts, USA

Didirikan

2010

Karyawan

6,000+

Situs Web

modernatx.com

Posisi Kaskade

Peran dalam Kaskade

late mover

Keterlambatan Tipikal

2-5 trading days

Moderna benefits from broader biopharma innovation sentiment but has no direct GLP-1 program; moves are sentiment-driven.

Lihat Kaskade Lengkap

Gambaran umum sektor — 제약 / 바이오

Berita sektor